Global Liquid Biopsy Market Size By Type (Test Suite, Equipment), By Application (Reference Laboratory, The Hospital), By Region, And Segment Forecasts, 2023 to 2032

lobal Liquid Biopsy Market Report Description

The Global Liquid Biopsy Market was valued at USD 3.9 billion in 2023 and is projected to reach USD 12.4 billion by 2031, growing at a CAGR of 15.6% during the forecast period (2023-2031). Liquid biopsy, a minimally invasive diagnostic procedure, analyzes circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers present in blood to detect and monitor cancer. Rising demand for early cancer detection and advancements in genomic profiling significantly drive market expansion.

Drivers:

Growing Incidence of Cancer Globally:

The increasing prevalence of cancer worldwide, coupled with the need for early diagnosis and effective treatment, significantly fuels market growth. Liquid biopsies provide rapid, less invasive methods for detecting and monitoring cancers.

Technological Advancements in Diagnostic Techniques:

Continuous developments in sequencing technologies and bioinformatics tools enhance the sensitivity and specificity of liquid biopsies, boosting adoption among healthcare providers.

Increasing Demand for Personalized Medicine:

Liquid biopsies facilitate personalized treatment plans by monitoring real-time tumor responses to therapies, thus promoting the widespread adoption of precision medicine.

Restraints:

Regulatory Challenges and Standardization Issues:

The absence of universally accepted standards for liquid biopsy tests, along with stringent regulatory approvals, can impede widespread adoption and market growth.

High Costs Associated with Advanced Diagnostic Methods:

Advanced liquid biopsy techniques, including next-generation sequencing (NGS), entail significant costs, limiting their accessibility and adoption, particularly in developing regions.

Opportunity:

Expansion in Emerging Markets:

Emerging economies such as India, China, and Brazil represent substantial growth potential due to expanding healthcare infrastructure and increasing healthcare expenditure.

Integration of AI and Big Data:

The integration of artificial intelligence and big data analytics with liquid biopsy techniques provides immense opportunities for improved accuracy, predictive analytics, and faster diagnosis.

Market by System Type Insights:

By type, the Circulating Tumor DNA (ctDNA) segment dominated the global market in 2023. ctDNA tests provide accurate tumor profiling and detection, driving robust demand across healthcare institutions. The Circulating Tumor Cells (CTCs) segment is also anticipated to experience significant growth owing to technological advancements in cell isolation techniques.

Market by End-use Insights:

Based on end-use, the Hospitals and Clinics segment accounted for the largest market share in 2023. Increasing adoption of advanced diagnostics and significant patient volume fuels growth in this segment. Meanwhile, the Diagnostic Laboratories segment is projected to grow rapidly, driven by an increasing demand for outsourced diagnostics and specialized testing services.

Market by Regional Insights:

North America led the global liquid biopsy market in 2023, supported by advanced healthcare infrastructure, significant R&D investments, and high adoption rates of advanced diagnostics. The Asia-Pacific region is expected to exhibit the highest growth during the forecast period, driven by rapidly improving healthcare systems, rising cancer incidence rates, and increased public and private investments.

Competitive Scenario:

Key players operating in the global liquid biopsy market include:

Guardant Health

Roche Diagnostics

Thermo Fisher Scientific, Inc.

Biocept, Inc.

Qiagen N.V.

Illumina, Inc.

Myriad Genetics, Inc.

Adaptive Biotechnologies

Grail, Inc.

Exact Sciences Corporation

These companies focus on strategic collaborations, technological innovations, and geographic expansion to strengthen their market positions.

Scope of Work – Global Liquid Biopsy Market

Key Market Developments:

July 2023: Guardant Health expanded its liquid biopsy product offerings, launching a new advanced test leveraging AI-driven analytics for enhanced cancer detection accuracy.

March 2023: Roche Diagnostics introduced an innovative circulating tumor DNA assay providing superior sensitivity for early-stage cancer detection.

January 2023: Illumina collaborated with healthcare providers to implement NGS-based liquid biopsy assays, enhancing personalized cancer diagnostics across North America.

FAQs:

What is the current market size of the Global Liquid Biopsy Market?

The market was valued at USD 3.9 billion in 2023.

What is the major growth driver of the Global Liquid Biopsy Market?

The primary growth driver is the rising global incidence of cancer coupled with the demand for non-invasive diagnostic techniques.

Which is the largest region during the forecast period in the Global Liquid Biopsy Market?

North America held the largest market share, driven by advanced healthcare infrastructure and high adoption of diagnostic technologies.

Which segment accounted for the largest market share in Global Liquid Biopsy Market?

The circulating tumor DNA (ctDNA) segment accounted for the largest market share in 2023.

Who are the key market players in the Global Liquid Biopsy Market?

Key players include Guardant Health, Roche Diagnostics, Thermo Fisher Scientific, Inc., Qiagen N.V., and Illumina, Inc.